BR9608207A - Inibidores de reticulação de fibrina e/ou transglutaminases - Google Patents

Inibidores de reticulação de fibrina e/ou transglutaminases

Info

Publication number
BR9608207A
BR9608207A BR9608207-0A BR9608207A BR9608207A BR 9608207 A BR9608207 A BR 9608207A BR 9608207 A BR9608207 A BR 9608207A BR 9608207 A BR9608207 A BR 9608207A
Authority
BR
Brazil
Prior art keywords
inhibitors
pro
leu
lys
sequence
Prior art date
Application number
BR9608207-0A
Other languages
English (en)
Inventor
Roy T Sawyer
Robert B Wallis
Lisa Seale
Sarah Finney
Original Assignee
Biopharm Res & Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharm Res & Dev Ltd filed Critical Biopharm Res & Dev Ltd
Publication of BR9608207A publication Critical patent/BR9608207A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

<B>INIBIDORES DE RETICULAçãO DE FIBRINA E/OU TRANSGLUTAMINASES<D> Inibidores que podem ser obtidos de tecidos ou secreções de sanguessugas tipicamente da ordem Rhychobdellida têm a seguinte seq³ência terminal: NH~ 2~-Lys-Leu-Leu-Pro-Cys-Lys-Glu-Y-His-Gln-Gly-Ile-Pro-Asn-Pro-Arg, em que Y representa qualquer seq³ência de aminoácido; ou um sal, derivado ou bioprecursor da seq³ência farmacêuticamente aceitável, ou um análogo ou homólogo dos mesmos. Devido à extrema potência deles na faixa nanomolar, os inibidores podem ser usados para tratar várias doenças onde a reticulação de proteína é importante. Os inibidores podem ser usados no tratamento da doença de Crohn, implante de tumor, arteriosclerose, microangiopatia trómbica, crescimento fibroso da pele, acne, formação de cicatrizes, glomerulonefrite, catarata ou infecção com nematóides microfilariais. Em particular, os inibidores podem ser usados para reduzir a estabilidade de vasos de modo que estejam mais sujeitos a lise por agentes trombolíticos.
BR9608207-0A 1995-05-05 1996-05-07 Inibidores de reticulação de fibrina e/ou transglutaminases BR9608207A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9509271.4A GB9509271D0 (en) 1995-05-05 1995-05-05 Blood clot stabilisation inhibitors
PCT/GB1996/001093 WO1996034890A2 (en) 1995-05-05 1996-05-07 Inhibitors of fibrin cross-linking and/or transglutaminases

Publications (1)

Publication Number Publication Date
BR9608207A true BR9608207A (pt) 2000-10-31

Family

ID=10774108

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608207-0A BR9608207A (pt) 1995-05-05 1996-05-07 Inibidores de reticulação de fibrina e/ou transglutaminases

Country Status (14)

Country Link
US (1) US6025330A (pt)
EP (1) EP0848719A2 (pt)
JP (1) JPH11505218A (pt)
KR (1) KR19990008348A (pt)
AU (1) AU723130B2 (pt)
BR (1) BR9608207A (pt)
CA (1) CA2220268A1 (pt)
CZ (1) CZ348197A3 (pt)
GB (1) GB9509271D0 (pt)
HU (1) HUP9900408A3 (pt)
NO (1) NO975080L (pt)
PL (1) PL323252A1 (pt)
SK (1) SK148797A3 (pt)
WO (1) WO1996034890A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056409A1 (en) * 1997-06-11 1998-12-17 Smithkline Beecham Corporation USE OF FACTOR XIIIa INHIBITORS TO TREAT ATHEROSCLEROSIS
DE10046187A1 (de) * 2000-09-13 2002-03-21 Univ Schiller Jena Verfahren zur Messung der Aktivität von Gerinnungsfaktor XIIIa
US20060246046A1 (en) * 2001-12-21 2006-11-02 Helmut Giersiefen Modified tridegins, production and use thereof as transglutaminase inihibitors
DE10163333B4 (de) * 2001-12-21 2007-01-25 Curacyte Ag Modifizierte Tridegine, ihre Herstellung deren Verwendung als Transglutaminase Inhibitoren und diese enthaltende Arzneimittel und Kombinationspräparate
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
US7691839B2 (en) 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US20100316764A1 (en) * 2009-06-10 2010-12-16 Engrain, LLC Flour supplement compositions and methods for preparing wheat flour
GB201318182D0 (en) * 2013-10-14 2013-11-27 Univ Nottingham Trent Inhibitor peptides
KR102131041B1 (ko) 2013-12-03 2020-07-08 (주)아모레퍼시픽 태양광 차단 기능성 물질 스크리닝 방법 및 태양광 차단 효능 평가 방법
WO2017089961A1 (pt) * 2015-11-24 2017-06-01 Universidade De Trás-Os-Montes E Alto Douro Método para a produção de farinhas de cereais e de proteínas enriquecidas em l-teanina e respectivos produtos
TWI825144B (zh) 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
CN110174513A (zh) * 2019-04-15 2019-08-27 中山大学附属第一医院 Tgm2在制备监测克罗恩病疾病活动的生物标志物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0347376B1 (en) * 1988-06-11 1994-03-23 Ciba-Geigy Ag Novel polypeptides with an anticoagulant activity
US5227469A (en) * 1990-02-14 1993-07-13 Genentech, Inc. Platelet aggregation inhibitors from the leech
US5328898A (en) * 1990-06-22 1994-07-12 Duke University Factor XIIIA fibrin binding fragments
WO1992013530A1 (en) * 1991-02-11 1992-08-20 Medicis Corporation Transglutaminase enzyme inhibitors
IT1264084B1 (it) * 1993-12-22 1996-09-10 Raggio Italgene Spa Peptide ad attivita' di substrato e/o inibitore dell'enzima transglutaminasi e suo uso in diagnosi e terapia.
DE4402631A1 (de) * 1994-01-29 1995-08-03 Boehringer Mannheim Gmbh Verfahren zur Bestimmung von Gerinnungsparametern

Also Published As

Publication number Publication date
US6025330A (en) 2000-02-15
GB9509271D0 (en) 1995-06-28
HUP9900408A3 (en) 2001-10-29
MX9708513A (es) 1998-08-30
NO975080L (no) 1998-01-02
CA2220268A1 (en) 1996-11-07
WO1996034890A2 (en) 1996-11-07
CZ348197A3 (cs) 1998-03-18
KR19990008348A (ko) 1999-01-25
AU5654696A (en) 1996-11-21
EP0848719A2 (en) 1998-06-24
NO975080D0 (no) 1997-11-04
HUP9900408A2 (hu) 1999-05-28
PL323252A1 (en) 1998-03-16
SK148797A3 (en) 1998-04-08
JPH11505218A (ja) 1999-05-18
WO1996034890A3 (en) 1997-10-23
AU723130B2 (en) 2000-08-17

Similar Documents

Publication Publication Date Title
Savage Jr et al. Proliferation of corneal epithelium induced by epidermal growth factor
BR9608207A (pt) Inibidores de reticulação de fibrina e/ou transglutaminases
EA200300824A1 (ru) Тиенил-, фурил-, пирролил- и дифенилсульфонамиды и их производные, модулирующие активность эндотелина
DK0696205T3 (da) Anvendelse af neuro-afledte fetale cellelinier til transplantationsterapi
DE69807349D1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
DE69534309D1 (de) Medizinische verwendung von matrixmetallproteine-inhibitoren zur hemmung von gewebekontraktion
ATE284959T1 (de) Unterbrechung der bindung der proteine mdm2 und p53 und entsprechende therapeutische anwendung
NO890408L (no) 3-indolpyrodruesyre-derivater og deres farmasoeytiske anvendelse.
ATE365550T1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
EA200001247A1 (ru) N-связанные сульфонамиды n-гетероциклических карбоновых кислот или изостеры карбоновых кислот
BR9708108A (pt) Preparado de combinação contendo 5-metilsoxazol-4-ácido carboxílico-(4-trifluorometil)-anilda e amida de ácido N-(4-trifluorometilfenil)-2-ciano-3-hidroxicrotônico
ATE223228T1 (de) Verwendung von latenz assoziierten peptiden in der herstellung eines medikaments zur verbesserung der wundheilung.
ATE83367T1 (de) Geraet zum schliessen von wunden.
BR9805151A (pt) Construções de ácidos nucleicos para a terapia do gene cuja atividade é afetada por inbidores de cinases dependentes de ciclina.
EA199700381A1 (ru) Диароматические соединения пропинила или диенила, промежуточные соединения, фармацевтические и косметические композиции на основе указанных соединений и применение косметических композиций
ES2151517T3 (es) Efectos de filamentos de actina sobre la estructura y lisis de coagulos de fibrina.
NO931186L (no) Terapeutisk aktive imidazolderivater, fremgangsmaate for deres fremstilling og anvendelse derav
DE68904462T2 (de) 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten.
PT1039884E (pt) Metodo para a prevencao e tratamento do miocardio aturdido
ATE112960T1 (de) Anthocyanidine zur behandlung von augenkrankheiten.
DE60030787D1 (de) Verwendung von l-carnitin als stabilitsator für proteine
ATE133860T1 (de) Tumor-nekrose-faktor-antagonist
ATE203680T1 (de) Konjugat zur behandlung von entzündungserkrankungen
ATE254919T1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law